Aortic Stenosis: Causes, Symptoms, Diagnosis & Treatment
Understanding the causes, molecular mechanisms, symptoms, diagnosis, and modern treatment of one of the most important valvular heart diseases.
The heart is an extraordinary muscular pump. With every heartbeat, it generates enough pressure to propel oxygen-rich blood through the aorta and into the systemic circulation. For this process to work efficiently, blood must pass through a series of valves that open and close in a precisely coordinated manner.
But what happens when one of these valves gradually becomes too narrow?
At first, the heart compensates. Its muscular walls thicken, allowing it to generate greater pressure and maintain blood flow. For years, this adaptation may be sufficient, and the affected person may experience no noticeable symptoms. Eventually, however, the same mechanisms that initially protect the heart can become harmful. The thickened heart muscle becomes stiffer, its oxygen requirements increase, and its ability to fill and pump blood efficiently may deteriorate. This is the fundamental problem behind aortic stenosis, a progressive valvular disease in which the opening of the aortic valve becomes restricted, obstructing blood flow from the left ventricle into the aorta.
Aortic stenosis is among the most important forms of valvular heart disease, particularly in older adults. Although it can remain silent for many years, advanced disease can lead to angina, loss of consciousness, heart failure, and potentially life-threatening cardiovascular complications.
Fortunately, modern cardiovascular medicine offers highly effective treatments. Surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) can relieve the obstruction and dramatically improve outcomes in appropriately selected patients.
Understanding aortic stenosis requires more than recognizing a narrowed valve. It means understanding how the disease develops at the cellular level, how the heart responds to increasing pressure, why symptoms eventually appear, and how clinicians determine the right time to intervene.
This article explores each of these questions, drawing on contemporary scientific literature and the 2025 European Society of Cardiology and European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines. [1–3]
Understanding the Aortic Valve: How Does It Normally Work?
To understand aortic stenosis, we first need to understand the normal anatomy and physiology of the aortic valve.
The human heart consists of four chambers: two atria and two ventricles. The left ventricle is responsible for pumping oxygenated blood into the systemic circulation through the aorta, the body's largest artery. Between the left ventricle and the aorta lies the aortic valve.
In most individuals, the aortic valve consists of three thin, flexible leaflets, or cusps:
Right coronary cusp
Left coronary cusp
Non-coronary cusp
The valve operates passively in response to pressure differences between the left ventricle and the aorta.
During systole
When the left ventricle contracts, ventricular pressure rises above aortic pressure. This pressure difference forces the aortic valve open, allowing blood to flow into the aorta.
A healthy aortic valve opens widely, permitting blood to pass with relatively little resistance.
During diastole
When the left ventricle relaxes, aortic pressure exceeds ventricular pressure.
The aortic valve closes, preventing blood from flowing backward into the ventricle.
This process repeats with every heartbeat.
A healthy aortic valve must therefore accomplish two essential tasks: open sufficiently to allow forward blood flow and close securely to prevent backward flow. When the valve fails to open adequately, the resulting condition is called aortic stenosis. When it fails to close properly, the resulting condition is called aortic regurgitation.
Although both affect the same valve, they produce fundamentally different hemodynamic problems.
What Exactly Is Aortic Stenosis?
Aortic stenosis (AS) is the pathological narrowing of the aortic valve opening, which creates an obstruction to blood leaving the left ventricle during systole.
Under normal circumstances, the adult aortic valve has an effective opening area of approximately 3–4 cm². As aortic stenosis progresses, the valve's effective opening becomes progressively smaller. In severe aortic stenosis, the calculated aortic valve area is commonly 1.0 cm² or less, although the diagnosis requires consideration of blood-flow velocity, pressure gradients, and other clinical findings.
Imagine trying to push water through a wide pipe compared with a pipe whose opening has become much narrower. To maintain a similar flow through the narrowed opening, a greater pressure difference is required. The same principle applies to the heart. As the aortic valve narrows, the left ventricle must generate increasingly high pressures to push blood through the restricted opening. This produces left ventricular pressure overload. Over time, chronic pressure overload initiates structural, functional, and molecular changes in the myocardium.
Importantly, aortic stenosis generally develops gradually. There is often a prolonged period during which the valve becomes increasingly abnormal without producing significant symptoms. This explains why some individuals may live with the disease for years before realizing that anything is wrong.
What Causes Aortic Stenosis?
Aortic stenosis is not a single disease process with one universal cause. Several conditions can produce narrowing of the aortic valve. The most important are degenerative calcific disease, congenital bicuspid aortic valve, and rheumatic heart disease.
Degenerative calcific aortic stenosis
Degenerative calcific aortic stenosis is the predominant cause of aortic stenosis in older adults in many high-income countries. For a long time, aortic valve calcification was considered primarily a passive consequence of aging, similar to the gradual deterioration of mechanical materials. We now know that this explanation is incomplete.
Calcific aortic valve disease is an active biological process involving endothelial dysfunction, lipid accumulation, inflammation, extracellular matrix remodeling, and the transformation of valve cells into cells capable of promoting mineral deposition. Over time, calcium accumulates within the valve leaflets, making them thicker, stiffer, and less mobile. Their ability to open fully during systole becomes progressively impaired.
Advanced age is a major risk factor, but several other factors are associated with calcific aortic valve disease, including hypertension, smoking, elevated lipoprotein(a), chronic kidney disease, and certain metabolic abnormalities.
Nevertheless, having these risk factors does not necessarily mean that an individual will develop aortic stenosis.
Bicuspid aortic valve
The normal aortic valve usually contains three cusps. However, approximately 1–2% of people are born with a bicuspid aortic valve, meaning that the valve has two functional leaflets rather than three. Bicuspid aortic valve is one of the most common congenital cardiac abnormalities. Because of its altered anatomy, the valve experiences abnormal mechanical forces and blood-flow patterns.
These abnormalities can accelerate leaflet degeneration and calcification, potentially leading to clinically significant stenosis at a younger age than is typical for degenerative tricuspid aortic valve disease. Some individuals develop severe stenosis during early or middle adulthood, whereas others retain adequate valve function for much longer. Bicuspid aortic valve is also important because it may coexist with enlargement of the ascending aorta. Consequently, patients with this condition require assessment not only of their aortic valve but also of the aortic root and ascending aorta.
Rheumatic heart disease
Rheumatic heart disease develops as a consequence of an abnormal immune response following infection with group A Streptococcus. Repeated or severe inflammatory injury can produce progressive scarring and deformation of the heart valves. In the aortic valve, this may cause thickening and fusion of the commissures, the regions where adjacent valve leaflets meet.
Unlike degenerative calcific stenosis, which primarily restricts leaflet motion through fibrosis and calcium deposition, rheumatic stenosis often involves commissural fusion.
Rheumatic disease frequently affects multiple valves, especially the mitral valve.
Although its prevalence has declined in many high-income countries, rheumatic heart disease remains an important cause of valvular pathology in several regions of the world.
Other causes
Less common causes and contributors include prior chest radiation, advanced chronic kidney disease with abnormal mineral metabolism, and certain inflammatory disorders.
Each of these conditions can influence the rate and pattern of valve deterioration.
How Does Aortic Stenosis Develop at the Molecular Level?
One of the most interesting discoveries in cardiovascular pathology is that calcific aortic stenosis involves biological mechanisms that resemble some aspects of atherosclerosis. However, the two diseases are not identical.
Research summarized by Banceu and colleagues describes a progressive process involving mechanical injury, inflammation, fibrosis, and calcification. [1]
Step 1: Endothelial dysfunction and mechanical stress
The aortic valve is covered by a thin layer of endothelial cells. These cells do more than form a physical barrier. They respond to blood-flow patterns, mechanical forces, inflammatory signals, and circulating molecules. Over time, abnormal mechanical stress and alterations in local shear stress can contribute to endothelial dysfunction. When the endothelial barrier becomes disturbed, the underlying valve tissue becomes more susceptible to the accumulation of circulating lipoproteins and inflammatory mediators. This creates an environment that favors further tissue injury.
Step 2: Lipid accumulation and inflammation
Low-density lipoprotein (LDL) and lipoprotein(a), commonly abbreviated Lp(a), have been identified in early calcific aortic valve lesions. Following their accumulation within valve tissue, these particles can undergo oxidative modification. Oxidized lipids promote inflammatory signaling and contribute to the recruitment and activation of immune cells, particularly macrophages. Inflammatory mediators subsequently influence the behavior of surrounding valve cells. This is an important distinction: calcific aortic stenosis is not simply calcium being deposited on an otherwise healthy valve. Inflammation and cellular remodeling are actively involved in its development.
Step 3: Activation of valvular interstitial cells
Within the aortic valve are specialized cells known as valvular interstitial cells (VICs).
Under normal conditions, these cells help maintain the structure and mechanical properties of the valve. During the development of calcific aortic valve disease, inflammatory and mechanical signals can alter their behavior. Some VICs acquire a myofibroblast-like phenotype, promoting extracellular matrix remodeling and fibrosis. Others undergo osteogenic differentiation, meaning that they begin expressing characteristics normally associated with bone-forming cells. Molecular pathways involving bone morphogenetic proteins, including BMP2, and regulatory systems involving NOTCH1 have been implicated in these processes. The result is a progressive transition from flexible valve tissue toward an increasingly rigid, fibrotic, and calcified structure.
Step 4: Calcification and loss of valve mobility
The accumulation of calcium-containing mineral deposits, primarily involving calcium phosphate in the form of hydroxyapatite, further increases leaflet stiffness. As the disease advances, calcium deposits may become extensive enough to severely restrict leaflet movement. The valve opening becomes smaller, and the resistance to blood flow increases. At this stage, the biological changes within the valve begin producing substantial hemodynamic consequences. An important concept is that the transition from inflammation to advanced calcification is not necessarily a simple, perfectly linear process. Multiple pathways overlap and reinforce one another. Fibrosis, mineralization, oxidative stress, and local inflammation may all contribute to disease progression.
How Aortic Stenosis Changes the Heart
Aortic stenosis begins as a disease of the valve, but its consequences extend throughout the cardiovascular system.
The most important effects occur in the left ventricle.
Increased afterload and pressure overload
Afterload refers, broadly, to the mechanical load against which a ventricle must contract to eject blood. When the aortic valve becomes stenotic, the left ventricle must overcome the additional resistance created by the narrowed valve. This increases the pressure required to maintain forward blood flow. As a result, left ventricular systolic pressure may become considerably higher than the pressure in the ascending aorta. The difference between these pressures reflects the obstruction created by the stenotic valve.
Concentric left ventricular hypertrophy
The heart initially responds to chronic pressure overload by increasing myocardial wall thickness. This process is known as concentric left ventricular hypertrophy (LVH).
To understand why this occurs, we can consider the simplified principle described by the law of Laplace. For a given ventricular pressure and chamber size, increasing wall thickness helps reduce the mechanical stress experienced by individual myocardial fibers. In other words, ventricular hypertrophy initially allows the heart to tolerate higher pressure while limiting wall stress. This is a compensatory response. However, compensation comes at a cost.
A thicker ventricular wall contains more myocardial tissue, which increases the heart's overall oxygen and metabolic requirements. Furthermore, hypertrophy is often accompanied by changes in myocardial architecture and progressive fibrosis.
Diastolic dysfunction
As the left ventricular wall becomes thicker and more fibrotic, it often becomes less compliant.Compliance describes how easily a chamber expands when it fills with blood. A stiff left ventricle requires a higher filling pressure to accommodate a given volume of blood. Consequently, left ventricular end-diastolic pressure can increase. This elevated pressure may be transmitted backward into the left atrium and pulmonary veins. When pulmonary venous pressure rises sufficiently, fluid can accumulate within the lungs, contributing to shortness of breath and, in advanced cases, pulmonary edema. Importantly, this can happen even when left ventricular ejection fraction remains normal. Therefore, a patient may develop heart failure symptoms despite having a seemingly preserved ejection fraction.
Myocardial ischemia
Aortic stenosis can also disturb the balance between myocardial oxygen supply and demand. The hypertrophied left ventricle requires more oxygen because it contains more muscle and must generate greater pressure.
At the same time, coronary blood-flow reserve may become impaired. Elevated intraventricular and filling pressures, myocardial fibrosis, and changes in the coronary microcirculation can all contribute to reduced oxygen delivery relative to demand.
This explains why aortic stenosis can produce angina even when there is no major obstructive coronary artery disease. However, coronary artery disease is also common in older patients with aortic stenosis, and both conditions may coexist.
Myocardial fibrosis and ventricular dysfunction
Over time, the consequences of chronic pressure overload may become increasingly difficult to reverse. Prolonged mechanical stress and neurohormonal activation contribute to myocardial remodeling. Cardiomyocytes may become dysfunctional, while fibrous tissue accumulates between myocardial cells.
Two broad patterns are particularly important:
1) Diffuse interstitial fibrosis: Fibrous tissue accumulates between surviving myocardial cells. Some of this remodeling may improve after the pressure overload is relieved.
2) Replacement fibrosis: Irreversibly injured or lost myocardial cells are replaced by scar tissue. This type of fibrosis is generally less reversible.
As the disease progresses, ventricular relaxation may deteriorate further, and contractile function can eventually decline. This may lead to reduced ejection fraction, worsening symptoms, arrhythmias, and heart failure.
The key principle is that aortic stenosis is not merely a narrowed valve; it is also a disease that progressively changes the structure and function of the myocardium.
These myocardial changes help explain why the timing of intervention matters so much.
What Are the Symptoms of Aortic Stenosis?
Aortic stenosis may remain asymptomatic for years. Symptoms generally become more concerning as the obstruction becomes severe, although some patients experience symptoms earlier because of associated cardiovascular conditions.
The classic symptoms are angina, syncope, and breathlessness related to heart failure.
Angina: Chest pain
Angina is typically described as chest discomfort, pressure, or tightness, often occurring during physical exertion.
In aortic stenosis, several mechanisms can contribute. The hypertrophied left ventricle has an increased oxygen requirement, while the heart's ability to increase coronary blood flow during exertion may be limited. Increased intramyocardial pressure and reduced coronary perfusion reserve further contribute to this mismatch. The result can be myocardial ischemia. Crucially, angina does not necessarily mean that the coronary arteries are obstructed, although coronary artery disease must still be considered and evaluated.
Syncope: Temporary loss of consciousness
Syncope is a sudden, temporary loss of consciousness caused by inadequate cerebral blood flow.
In severe aortic stenosis, the left ventricle may be unable to increase cardiac output sufficiently during exertion. Normally, exercise causes peripheral blood vessels to dilate while cardiac output increases to maintain adequate blood pressure. In severe aortic stenosis, the fixed obstruction may limit the increase in forward blood flow.
If peripheral vascular resistance falls without a sufficient increase in cardiac output, systemic blood pressure may decrease. This can reduce cerebral perfusion and cause syncope.
Arrhythmias and other mechanisms may also contribute to loss of consciousness in patients with aortic stenosis.
Syncope in someone with known or suspected severe aortic stenosis warrants prompt medical evaluation.
Dyspnea: Shortness of breath
Shortness of breath is one of the most common symptoms associated with clinically significant aortic stenosis.
Initially, it may appear only during exertion, such as climbing stairs or walking uphill. As the disease advances, breathlessness may develop during ordinary daily activities or even at rest.
The primary mechanism often involves diastolic dysfunction. As left ventricular filling pressures rise, pressure is transmitted backward into the pulmonary circulation. This can cause pulmonary congestion and impair normal gas exchange.
In more advanced disease, impaired ventricular contractility may further reduce cardiac output.
Fatigue and reduced exercise tolerance
Not every patient develops obvious chest pain or syncope. Some individuals instead notice a gradual reduction in their physical capacity. Activities that once felt easy may become unexpectedly tiring. This can be particularly difficult to recognize in older adults because the reduction in activity may occur slowly.
For example, a person who previously walked several kilometers each day may gradually begin taking shorter walks without considering the possibility of an underlying cardiovascular condition.
This is one reason careful history-taking is important.
Other possible manifestations
Advanced aortic stenosis may also be associated with palpitations, dizziness, peripheral edema, and symptoms related to atrial fibrillation or other arrhythmias. Severe breathlessness at rest, new chest pain, or fainting should never be dismissed as normal aging.
Seek urgent medical attention for new or severe chest pain, fainting, or severe difficulty breathing. These symptoms may indicate aortic stenosis or another serious cardiovascular emergency.
How Is Aortic Stenosis Diagnosed?
The diagnosis begins with the patient's history and physical examination, but echocardiography is the central investigation.
Physical examination
One of the characteristic findings of aortic stenosis is a systolic ejection murmur.
Classically, the murmur is described as crescendo–decrescendo in shape, meaning that its intensity rises and then falls during systole. It is usually heard most prominently over the right upper sternal border and frequently radiates toward the carotid arteries.
In more advanced disease, clinicians may identify a delayed carotid upstroke, reduced intensity of the aortic component of the second heart sound, or a fourth heart sound associated with reduced ventricular compliance.
However, physical examination alone cannot reliably determine disease severity.
In patients with substantially reduced cardiac output, even severe aortic stenosis may produce a relatively soft murmur.
This is why imaging is essential.
Transthoracic echocardiography
Transthoracic echocardiography (TTE) is the primary diagnostic tool for assessing aortic stenosis.
Using ultrasound, clinicians can visualize the valve, assess leaflet movement, measure blood-flow velocity, estimate pressure gradients, and calculate the aortic valve area.
Echocardiography also provides information about left ventricular function, wall thickness, and other valvular abnormalities.
Three measurements are especially important.
1) Peak aortic jet velocity (Vmax): This represents the highest measured velocity of blood passing through the aortic valve. As the effective valve opening narrows, velocity generally increases, provided sufficient blood flow is present.
2) Mean transvalvular pressure gradient: This estimates the average pressure difference across the aortic valve during systole. Higher gradients generally indicate a more severe obstruction under normal-flow conditions.
3) Aortic valve area (AVA): This estimates the effective area through which blood passes. A smaller area generally indicates more severe stenosis. The valve area is commonly calculated using the continuity equation, which is based on the principle that blood flow through the left ventricular outflow tract must equal flow through the aortic valve in the absence of significant intervening flow loss.
No single measurement should be interpreted in isolation.
How Is the Severity of Aortic Stenosis Classified?
Aortic stenosis is commonly classified as mild, moderate, or severe according to echocardiographic findings.
Measurement | Mild | Moderate | Severe high-gradient AS |
Peak aortic velocity | 2.0–2.9 m/s | 3.0–3.9 m/s | ≥4.0 m/s |
Mean gradient | <20 mmHg | 20–39 mmHg | ≥40 mmHg |
Aortic valve area | Usually >1.5 cm² | 1.0–1.5 cm² | ≤1.0 cm² |
These are commonly used diagnostic ranges, not an absolute rule requiring every measurement to fall into the same category. Aortic valve sclerosis without significant stenosis is generally associated with a peak velocity below 2.0 m/s.
Very severe aortic stenosis is commonly characterized by a peak velocity greater than 5.0 m/s or a mean gradient of at least 60 mmHg.
It is important to understand that the velocity and pressure gradient depend on blood flow.
This introduces one of the most important complexities in the diagnosis of aortic stenosis.
Low-flow, low-gradient aortic stenosis
In some patients, the aortic valve area appears severely reduced, but the measured pressure gradient is lower than expected.
How can a severely narrowed valve produce a relatively low gradient? The explanation often lies in the amount of blood passing through the valve.
If the left ventricle ejects relatively little blood, there may be insufficient flow to generate a high velocity or gradient, even when the valve is severely narrowed. This creates a diagnostic challenge.
Low-flow, low-gradient aortic stenosis can occur in patients with reduced ejection fraction. However, it can also occur despite a preserved ejection fraction, sometimes called paradoxical low-flow, low-gradient aortic stenosis.
In this setting, ventricular concentric remodeling, reduced chamber size, and impaired ventricular filling may reduce stroke volume despite apparently preserved systolic function.
A commonly used definition of low flow is a stroke volume index of 35 mL/m² or less.
Importantly, a calculated small valve area with a low gradient does not automatically establish that the stenosis is truly severe. Measurement errors, altered flow conditions, and pseudo-severe stenosis must be considered.
Dobutamine stress echocardiography
In selected patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction, low-dose dobutamine stress echocardiography can help clarify severity. Dobutamine increases myocardial contractility and may increase forward flow.
If increasing flow causes the valve area to expand substantially, the apparent stenosis may be partly explained by inadequate valve opening under low-flow conditions rather than fixed severe obstruction. This is often called pseudo-severe aortic stenosis.
If the valve remains significantly restricted despite increased flow, true severe stenosis becomes more likely. The interpretation is more complex when contractile or flow reserve is absent, and additional imaging may be required.
Cardiac computed tomography
Cardiac computed tomography (CT) is another important investigation, particularly when echocardiographic measurements are discordant. CT can quantify aortic valve calcification using an Agatston calcium score.
According to contemporary European guidance, calcium scores above approximately 2,000 Agatston units in men and 1,200 in women strongly support severe aortic stenosis in an appropriate clinical context.Higher scores provide even greater diagnostic specificity.
However, these thresholds must be interpreted carefully in patients with certain valve morphologies or conditions in which severe narrowing may occur without extensive calcium deposition.
CT is also central to planning transcatheter valve replacement because it allows detailed assessment of the aortic annulus, coronary artery origins, aortic root, and peripheral vascular access.
Other investigations
Electrocardiography may demonstrate left ventricular hypertrophy, conduction abnormalities, or atrial fibrillation.
Cardiac magnetic resonance imaging can help evaluate ventricular volumes, myocardial function, and myocardial fibrosis.
Blood tests such as BNP or NT-proBNP may provide additional information regarding myocardial stress and prognosis.
Coronary imaging may be required before valve intervention to identify significant coronary artery disease.
Together, these investigations allow clinicians to assess not just the valve but the overall cardiovascular consequences of the disease. [1,3]
How Quickly Does Aortic Stenosis Progress?
Aortic stenosis typically develops over many years, but progression rates vary considerably.
Some individuals experience relatively slow progression, while others develop worsening obstruction over a shorter period.
Aortic valve calcification, baseline disease severity, age, and other cardiovascular or metabolic factors can influence progression.
During the early phases, aortic sclerosis may be present without substantial hemodynamic obstruction.
As fibrosis and calcification accumulate, leaflet mobility declines and stenosis progresses.
Eventually, the increased resistance can produce substantial ventricular pressure overload.
There is no universally predictable timeline from mild stenosis to severe disease.
This uncertainty is one reason periodic echocardiographic surveillance is important.
The most clinically significant transition occurs when severe aortic stenosis becomes symptomatic or begins causing demonstrable ventricular dysfunction.
What happens if severe aortic stenosis is left untreated?
Untreated symptomatic severe aortic stenosis is associated with a poor prognosis. The obstruction continues to expose the left ventricle to excessive pressure, potentially worsening myocardial fibrosis, ventricular dysfunction, and heart failure.
Historically, survival after the onset of classic symptoms was often described in terms of only a few years without valve replacement. However, historical estimates should not be interpreted as an exact prediction for an individual patient. Prognosis depends on disease severity, ventricular function, associated conditions, and the nature of the symptoms.
Modern evidence consistently supports timely valve intervention in suitable patients with symptomatic severe disease.
When Does Aortic Stenosis Require Intervention?
One of the most important questions in managing aortic stenosis is determining when valve replacement becomes necessary.
It is not enough to know that the valve is narrowed.
Clinicians must evaluate disease severity, symptoms, ventricular function, procedural risk, and expected outcomes.
Symptomatic severe aortic stenosis
In patients with confirmed severe, high-gradient aortic stenosis and symptoms attributable to the valve disease, intervention is strongly recommended when the expected benefit justifies the procedure.
Valve replacement addresses the mechanical obstruction responsible for the disease. Medication alone cannot provide an equivalent correction.
Asymptomatic severe aortic stenosis
The management of patients with severe aortic stenosis who do not report symptoms is more complex.
Traditionally, patients with preserved ventricular function and no symptoms were often managed with careful surveillance until symptoms or other indications appeared. However, newer clinical trials have challenged the assumption that waiting is always the best strategy.
The 2025 ESC/EACTS guidelines recommend intervention in asymptomatic severe aortic stenosis when left ventricular ejection fraction falls below 50% without another explanation.
The guidelines also state that early intervention should be considered in selected patients with severe high-gradient aortic stenosis, preserved ejection fraction, and low procedural risk as an alternative to active surveillance.
Several findings may further support earlier intervention, including:
Very severe stenosis, such as a mean gradient of at least 60 mmHg or peak velocity greater than 5.0 m/s.
Severe valve calcification accompanied by rapid progression.
Markedly elevated BNP or NT-proBNP attributable to the valve disease.
Ejection fraction below 55% without another cause.
An abnormal exercise-test blood-pressure response.
Exercise testing may also reveal symptoms that were not apparent during ordinary daily activities.
These recommendations represent an important development in modern management. The goal is not necessarily to operate on every asymptomatic patient immediately. Rather, it is to identify individuals in whom the risks of continued pressure overload may outweigh the risks of intervention.
Careful shared decision-making remains essential. [3]
Can Aortic Stenosis Be Treated With Medication?
This is one of the most important questions patients ask.
At present, no routinely established medication has been demonstrated to reliably reverse calcific aortic stenosis or halt its progression sufficiently to replace valve intervention.
This may seem surprising because aortic stenosis shares several biological features with atherosclerosis. Statins, for example, lower LDL cholesterol and reduce the risk of major atherosclerotic cardiovascular events.
However, clinical trials have not demonstrated that statin therapy reliably prevents the progression of established calcific aortic stenosis. This does not mean statins are useless in patients with aortic stenosis. They remain important when prescribed for established indications such as coronary artery disease or elevated cardiovascular risk.
They simply should not be presented as a proven treatment for the valvular obstruction itself.
Managing associated cardiovascular conditions
Although medications cannot reliably eliminate the stenosis, they may still play an important role. Treatment of hypertension, coronary artery disease, atrial fibrillation, or heart failure can improve overall cardiovascular management.
In patients who develop heart failure with reduced ejection fraction, guideline-directed medical therapy may include renin–angiotensin system inhibitors or angiotensin receptor–neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, when appropriate.
However, drug selection and dosing require individualized assessment because patients with advanced aortic stenosis may be especially sensitive to abrupt changes in blood pressure or circulating volume.
These treatments should not delay indicated valve replacement.
Surgical Aortic Valve Replacement (SAVR)
Surgical aortic valve replacement has been a cornerstone of treatment for severe aortic stenosis for decades. The procedure involves removing the diseased aortic valve and implanting a prosthetic valve.
In conventional surgery, the surgeon accesses the heart through a median sternotomy. The procedure is generally performed using cardiopulmonary bypass, which temporarily maintains circulation and oxygenation while the heart is stopped.
The diseased valve leaflets are excised, and the replacement prosthesis is secured within the aortic annulus. After implantation, the surgeon verifies valve function, restores normal circulation through the heart, and completes the operation.
SAVR offers several important advantages. It allows direct removal of the calcified valve and permits the surgeon to address other structural abnormalities during the same procedure.
For example, patients with significant coronary artery disease may undergo coronary artery bypass grafting at the same operation. Patients with aortic root or ascending aortic disease may also require additional aortic surgery.
SAVR remains especially important in younger patients, individuals with anatomy unsuitable for TAVI, and those requiring complex concomitant cardiac procedures.
Minimally invasive surgical approaches
Not every surgical aortic valve replacement requires a full median sternotomy. Selected patients may undergo minimally invasive surgery through a partial sternotomy or a small right-sided thoracic incision. These approaches can reduce surgical access trauma and may facilitate faster recovery in suitable patients.
However, minimally invasive surgery is still cardiac surgery and generally requires cardiopulmonary bypass.
The choice of surgical approach depends on patient anatomy, procedural complexity, and the expertise of the surgical team.
Transcatheter Aortic Valve Implantation (TAVI)
One of the most significant advances in modern cardiovascular medicine has been the development of transcatheter aortic valve implantation.
TAVI, also called transcatheter aortic valve replacement (TAVR), allows a replacement valve to be implanted without conventional open-heart surgery.
The first successful human transcatheter aortic valve implantation was performed in 2002. Since then, improvements in valve design, imaging, delivery systems, and procedural techniques have dramatically expanded its clinical use.
How does TAVI work?
In the most common approach, a catheter is introduced through an artery in the groin, usually the femoral artery. The catheter is advanced through the arterial system toward the heart.
A compressed biological valve mounted on a delivery system is positioned within the diseased native aortic valve. Once correctly positioned, the new valve is expanded, either using a balloon or through a self-expanding frame. The implanted valve pushes the diseased native leaflets aside and creates a new functional opening for blood to pass through.
The procedure generally does not require the native valve to be surgically removed. Because TAVI avoids a conventional sternotomy and usually does not require cardiopulmonary bypass, recovery is often faster than after traditional surgical replacement.
Advantages of TAVI
For appropriately selected patients, TAVI offers several advantages, including a less invasive approach, shorter hospital stays in many cases, and faster early recovery.
Randomized clinical trials have demonstrated that TAVI can achieve outcomes comparable to SAVR in selected patient populations across a range of surgical risk categories.
However, these results must be interpreted within the characteristics of the studied populations.
Limitations and complications
TAVI is not suitable for every patient.
Potential complications include vascular injury, bleeding, stroke, new conduction abnormalities requiring a permanent pacemaker, and leakage around the implanted valve, known as paravalvular regurgitation.
Coronary artery obstruction is uncommon but potentially catastrophic.
Anatomical factors such as low coronary artery origins, extensive leaflet calcification, and unfavorable aortic root dimensions can increase procedural difficulty.
Another concern is the long-term durability of transcatheter valves, particularly in younger patients who may live for several decades after implantation.
Although increasingly reassuring medium-term data exist, the long-term implications of repeated valve interventions remain important.
Consequently, the least invasive procedure is not automatically the best long-term option for every patient. [1,2]
TAVI vs. SAVR: Which Is Better?
There is no universal answer.
The choice between TAVI and SAVR is influenced by multiple factors, including age, life expectancy, surgical risk, valve anatomy, coronary artery disease, additional cardiac conditions, and patient preferences.
According to the 2025 ESC/EACTS guidelines, SAVR is recommended for patients younger than 70 years who have low surgical risk.
For patients aged 70 years or older with a tricuspid aortic valve, suitable anatomy, and feasible transfemoral access, TAVI is recommended.
Other patients require individualized Heart Team assessment.
These are European recommendations, and practice may differ between countries and clinical guidelines.
A comparison of the two approaches
Feature | SAVR | TAVI |
Access | Surgical incision | Usually catheter through femoral artery |
Native valve | Surgically removed | Usually left in place |
Cardiopulmonary bypass | Usually required | Usually not required |
Early recovery | Generally longer | Generally faster |
Mechanical valve option | Yes | No established routine mechanical TAVI option |
Additional cardiac surgery | Can be performed simultaneously | Requires separate or staged interventions |
Pacemaker requirement | Possible | Generally more frequent |
Long-term considerations | Prosthesis choice and possible future surgery | Valve durability, coronary access, repeat TAVI feasibility |
A patient with severe aortic stenosis and extensive multivessel coronary artery disease may benefit from SAVR combined with coronary artery bypass grafting.
A substantially older patient with severe symptomatic stenosis, a tricuspid valve, and favorable transfemoral anatomy may be particularly well suited to TAVI.
A younger patient with a bicuspid valve and significant ascending aortic enlargement may benefit from surgery that addresses both the valve and aorta.
The central principle is that aortic valve replacement should be planned as part of a patient's lifetime cardiovascular treatment strategy, not simply as an isolated procedure.
Mechanical vs. Biological Heart Valves
When surgical valve replacement is selected, another important decision concerns the type of prosthetic valve. Two major categories are available: mechanical and biological valves.
Mechanical valves
Mechanical valves are constructed from highly durable synthetic materials, commonly including pyrolytic carbon. Their principal advantage is durability. Unlike biological tissue valves, mechanical valves are not subject to the same form of progressive tissue calcification and degeneration.
However, mechanical valves create a risk of thrombus formation. Patients with mechanical heart valves therefore require lifelong anticoagulation, generally using a vitamin K antagonist such as warfarin.
This requires monitoring of the international normalized ratio (INR), attention to medication interactions, and consideration of bleeding risk.
Direct oral anticoagulants are not an established substitute for vitamin K antagonists in patients with mechanical heart valves.
Biological valves
Biological prostheses, also known as bioprosthetic valves, are commonly manufactured from treated bovine pericardial tissue or porcine valve tissue. Their major advantage is that they generally do not require lifelong anticoagulation solely because of the prosthesis.
However, anticoagulant or antiplatelet treatment may still be necessary during specific postoperative periods or for unrelated conditions such as atrial fibrillation.
Their principal limitation is structural valve deterioration. Over time, biological leaflets can become calcified, torn, thickened, or otherwise dysfunctional. This may produce recurrent stenosis or regurgitation and eventually require further intervention.
Why age matters
Younger individuals generally have longer expected lifespans and may face a greater lifetime probability of biological valve deterioration and reintervention. Older patients may derive substantial benefit from avoiding the burden of lifelong mechanical-valve anticoagulation.
However, age alone should not determine prosthesis selection.
Bleeding risk, pregnancy considerations, patient preferences, expected longevity, and the feasibility of future interventions all matter.
What is valve-in-valve TAVI?
When an implanted biological valve deteriorates, it may sometimes be possible to insert a new transcatheter valve inside the existing prosthesis. This is called valve-in-valve TAVI. The technique can avoid repeat open-heart surgery in selected patients.
However, it is not universally feasible. A small original prosthesis may leave insufficient room for a new valve, creating a high residual pressure gradient or prosthesis–patient mismatch.
Coronary artery obstruction and difficulty accessing the coronary arteries can also become concerns.
This is why clinicians must consider possible future interventions when selecting the first valve.
Beyond Conventional Valve Replacement: Emerging Treatments
Although SAVR and TAVI dominate contemporary treatment, several other approaches are being studied or increasingly used in selected patients.
The review by Liu and colleagues provides an extensive overview of these developments. [2]
The Ross procedure
The Ross procedure involves replacing the diseased aortic valve with the patient's own pulmonary valve. A donor pulmonary valve is then implanted in the pulmonary position. This is known as a pulmonary autograft procedure.
The concept is particularly attractive in selected younger patients because the patient's living pulmonary valve can provide excellent hemodynamic performance in the aortic position.
In experienced centers, long-term studies have reported favorable survival and valve-related outcomes.
However, the Ross procedure is technically demanding and transforms a single-valve problem into an operation involving both the aortic and pulmonary positions. Long-term follow-up is necessary because either position may require future intervention. Therefore, the Ross procedure is generally considered for carefully selected patients at specialized centers.
The Ozaki procedure
The Ozaki procedure is a form of aortic valve neocuspidization. Instead of implanting a conventional prosthetic valve, the surgeon reconstructs new aortic valve leaflets using specially prepared pericardial tissue, often taken from the patient. The technique aims to restore effective valve function while avoiding conventional prosthetic valve implantation.
Early and medium-term clinical outcomes have been encouraging in selected patients. However, robust long-term evidence is still developing, and the procedure has not replaced conventional SAVR or TAVI as a standard universal treatment.
Balloon aortic valvuloplasty
Balloon aortic valvuloplasty involves advancing a balloon catheter across the stenotic aortic valve and inflating it to temporarily enlarge the opening. Unlike valve replacement, the procedure does not create a new valve. The improvement is often temporary, and restenosis may occur. Consequently, balloon valvuloplasty is primarily used as a bridging procedure in selected circumstances.
For example, it may be considered in patients requiring stabilization before definitive intervention or in certain urgent clinical situations.
It may also provide palliative symptom relief when definitive replacement is not feasible.
Polymeric and tissue-engineered heart valves
Researchers are developing new valve materials that may eventually combine the durability of mechanical valves with the reduced anticoagulation burden of biological valves.
Polymeric heart valves use engineered synthetic materials designed to withstand repeated leaflet motion. Tissue-engineered valves take a different approach. They may use biological or synthetic scaffolds capable of supporting cellular growth and tissue remodeling. Ideally, future tissue-engineered valves could become more biologically integrated and adapt over time.
However, these technologies remain in relatively early stages of clinical development.
Short-term feasibility does not yet establish decades of durability or broad clinical safety.
Robotic and minimally invasive techniques
Robotic-assisted surgical aortic valve replacement is another developing field. Robotic systems can provide high-definition visualization and facilitate precise manipulation through smaller surgical access points. Early studies have demonstrated feasibility and encouraging procedural outcomes in selected patients.
However, larger studies and long-term comparative data are needed before broad claims of superiority over conventional surgery or TAVI can be established.
Non-invasive ultrasound therapy
An experimental approach being investigated for calcific aortic stenosis involves applying externally delivered therapeutic ultrasound to calcified valve tissue. The aim is to modify the mechanical properties of the calcified valve and potentially improve leaflet mobility without implanting a new prosthesis.
Early clinical investigations have reported encouraging feasibility and hemodynamic findings.
However, these studies have involved relatively small patient groups, and the durability and clinical importance of the observed changes remain uncertain.
Non-invasive ultrasound therapy should therefore be considered investigational rather than an established alternative to valve replacement.
What Happens After Aortic Valve Replacement?
A successful valve intervention can substantially reduce the pressure gradient across the aortic valve. However, relieving the obstruction is only the beginning of long-term cardiovascular care.
Reverse ventricular remodeling
After valve replacement, the left ventricle no longer needs to generate the same excessive pressure to eject blood. This reduction in afterload may allow the hypertrophied myocardium to remodel.
Over time, left ventricular mass can decrease, and diastolic function may improve. Patients with reduced ventricular function caused predominantly by excessive afterload may also experience an improvement in ejection fraction.
Nevertheless, recovery is not always complete.
Established replacement fibrosis and other pre-existing myocardial abnormalities may persist even after successful valve replacement. This reinforces the importance of performing intervention before irreversible myocardial damage becomes extensive.
Cardiac rehabilitation
Cardiac rehabilitation can play an important role following valve intervention.
Programs may include supervised exercise, cardiovascular risk-factor management, medication education, and gradual return to ordinary activities. The timing and intensity of rehabilitation depend on the type of intervention, recovery, and individual clinical condition. Patients recovering from conventional surgery generally need more time for wound healing and recovery of physical function than patients undergoing uncomplicated transfemoral TAVI.
Nevertheless, both groups benefit from appropriate clinical follow-up.
Long-term surveillance
Patients with biological valve prostheses require periodic evaluation because structural valve deterioration may occur over time.
The 2025 European guidelines recommend an early echocardiographic examination after valve replacement to establish baseline prosthetic function, followed by annual clinical and echocardiographic surveillance for patients with bioprostheses.
Patients with mechanical valves also require ongoing specialist care, particularly to ensure safe anticoagulation.
Regardless of the prosthesis, new breathlessness, reduced exercise capacity, fever, or other concerning symptoms should prompt clinical assessment.
Patients with prosthetic heart valves are also at increased risk of infective endocarditis and should maintain good dental hygiene and follow applicable recommendations concerning antibiotic prophylaxis for certain dental procedures.
Valve replacement is highly effective, but it does not eliminate the need for lifelong cardiovascular care.
Can Aortic Stenosis Be Prevented?
Unfortunately, there is currently no proven strategy that guarantees prevention of calcific aortic stenosis. This reflects the complex biological nature of the disease. Age, genetic susceptibility, congenital valve abnormalities, inflammatory pathways, and metabolic factors all contribute.
However, maintaining cardiovascular health remains important. Controlling blood pressure, avoiding smoking, engaging in appropriate physical activity, and treating established lipid disorders or diabetes can reduce overall cardiovascular risk. These interventions should not be interpreted as proven methods of reversing established valve calcification.
Patients with known bicuspid aortic valves may require periodic assessment of the valve and ascending aorta. Because bicuspid aortic valve can occur in families, echocardiographic screening of first-degree relatives may be appropriate according to clinical recommendations.
In selected patients, measurement of Lp(a) may also provide valuable information about inherited cardiovascular risk.
Perhaps most importantly, patients diagnosed with aortic stenosis should understand the need for ongoing monitoring, even when they feel completely healthy.
Conclusion: A Disease of the Valve and the Heart
Aortic stenosis provides an important example of how a localized anatomical abnormality can gradually affect an entire organ. What begins as progressive thickening, fibrosis, and calcification of the aortic valve can eventually produce profound changes in the left ventricle.
Initially, concentric hypertrophy allows the heart to compensate for increasing pressure overload. Over time, however, the same adaptation can lead to increased oxygen demand, impaired relaxation, myocardial fibrosis, and eventually ventricular dysfunction.
The development of symptoms often indicates that the cardiovascular system is struggling to compensate for the obstruction.
Fortunately, advances in cardiac surgery, transcatheter intervention, and cardiovascular imaging have transformed the management of aortic stenosis.
Surgical aortic valve replacement remains a fundamental treatment, particularly for younger patients and those requiring additional cardiac procedures.
TAVI has expanded effective treatment options for many older patients and individuals with suitable anatomy.
Meanwhile, developments in polymeric valves, tissue engineering, the Ross procedure, minimally invasive surgery, and molecular therapeutics may further reshape the treatment landscape.
Yet one of the most important principles remains unchanged:
The objective is not simply to replace a severely narrowed valve. It is to relieve the obstruction at the right time, preserve myocardial function, prevent irreversible cardiac damage, and provide the best possible long-term outcome for the individual patient.
Understanding the biology of aortic stenosis is the first step toward understanding why these decisions matter.
References
1. Banceu CM, Cristutiu D, Gurzu S, Harpa MM, Banceu D, Suciu H. (2025). Aortic Stenosis: Diagnosis, Molecular Mechanisms and Therapeutic Strategies—A Comprehensive Review. Journal of Clinical Medicine, 14(14), 4949.
2. Liu P, Wang H, Wang S, Shan Y, Dong N, Wang Y. (2025). Current Landscape in the Management of Aortic Stenosis. Journal of Clinical Medicine, 14(10), 3542.
3. Praz F, Borger MA, Lanz J, et al. (2025). 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 46, 4635–4736.
Medical Disclaimer
This article is intended solely for educational and informational purposes. It is based on published scientific literature and clinical guidelines but does not constitute personalized medical advice, diagnosis, or treatment.
Clinical decisions concerning aortic stenosis require evaluation by qualified healthcare professionals and must consider individual symptoms, medical history, diagnostic findings, and current clinical guidelines.
Readers should not initiate, discontinue, or modify any medical treatment based solely on the information presented here. Anyone experiencing concerning cardiovascular symptoms should seek appropriate medical attention.
Comments